FGFR2 and hereditary pheochromocytoma-paraganglioma: Tumors with dominant FGFR2 amplification included STAD (4.09%), OV (1.88%), pheochromocytoma and paraganglioma (PCPG) (1.12%), ESCA (0.55%), and PAAD (0.54%).